×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ICAD

iCAD Stock Forecast, Price & News

$3.95
-0.05 (-1.25%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.90
$4.08
50-Day Range
$3.27
$4.56
52-Week Range
$2.91
$17.62
Volume
97,075 shs
Average Volume
226,353 shs
Market Capitalization
$99.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

iCAD Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
216.5% Upside
$12.50 Price Target
Short Interest
Healthy
8.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of iCAD in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.44 out of 5 stars

Computer And Technology Sector

572nd out of 936 stocks

Surgical & Medical Instruments Industry

101st out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

iCAD logo

About iCAD (NASDAQ:ICAD)

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

ICAD Stock News Headlines

This Has Won 99.1% Of Trades Over 3 Years
Video reveals the most powerful trade you’ve NEVER heard of. Released every Tuesday, it could DOUBLE your money by Friday. In past 3 years, it’s won 321 out of 324 of these trades, with the majority making 100%+ every 3-10 days. See how a simple 10-minute trade on Tue could double your money by Fri. Watch Video Now For Full Details.
Analysts Set iCAD, Inc. (NASDAQ:ICAD) Target Price at $16.50
This Has Won 99.1% Of Trades Over 3 Years
Video reveals the most powerful trade you’ve NEVER heard of. Released every Tuesday, it could DOUBLE your money by Friday. In past 3 years, it’s won 321 out of 324 of these trades, with the majority making 100%+ every 3-10 days. See how a simple 10-minute trade on Tue could double your money by Fri. Watch Video Now For Full Details.
5 Growth Stocks to Buy Now - InvestorPlace
iCAD Announces CFO Transition - GlobeNewswire
iCAD Announces CFO Transition
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ICAD
Employees
136
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
7/02/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+216.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.8
Research Coverage
5 Analysts

Profitability

Net Income
$-11.24 million
Pretax Margin
-40.42%

Debt

Sales & Book Value

Annual Sales
$33.64 million
Book Value
$1.85 per share

Miscellaneous

Free Float
22,034,000
Market Cap
$99.47 million
Optionable
Optionable
Beta
1.28

Social Links















iCAD Frequently Asked Questions

Should I buy or sell iCAD stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" iCAD stock.
View analyst ratings for iCAD
or view top-rated stocks.

What is iCAD's stock price forecast for 2022?

5 brokers have issued 12-month price targets for iCAD's shares. Their ICAD stock forecasts range from $8.00 to $16.00. On average, they predict iCAD's stock price to reach $12.50 in the next year. This suggests a possible upside of 216.5% from the stock's current price.
View analysts' price targets for iCAD
or view top-rated stocks among Wall Street analysts.

How has iCAD's stock price performed in 2022?

iCAD's stock was trading at $7.20 on January 1st, 2022. Since then, ICAD shares have decreased by 45.1% and is now trading at $3.95.
View the best growth stocks for 2022 here
.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for iCAD
.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) issued its quarterly earnings data on Wednesday, May, 11th. The technology company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The technology company had revenue of $7.52 million for the quarter, compared to analysts' expectations of $7.50 million. iCAD had a negative trailing twelve-month return on equity of 26.45% and a negative net margin of 40.43%.
View iCAD's earnings history
.

What guidance has iCAD issued on next quarter's earnings?

iCAD updated its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.50 million-$7.50 million, compared to the consensus revenue estimate of $7.45 million.

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Ms. Stacey M. Stevens, Pres, CEO & Director (Age 54, Pay $366.35k) (LinkedIn Profile)
  • Mr. Jonathan Go, Chief Technology Officer (Age 59, Pay $330.13k) (LinkedIn Profile)
  • Mr. Stephen P. Sarno, Interim Chief Financial Officer (Age 55)
  • Ms. Annette L. Heroux, VP of Admin. (Age 65)
  • Mr. Anthony Takazawa, Director of Investor Relations
  • Brian Testa, Chief People Officer
  • Mr. Jeffrey Sirek, Chief Commercial Officer

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD CEO Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among iCAD's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $3.95.

How much money does iCAD make?

iCAD (NASDAQ:ICAD) has a market capitalization of $99.47 million and generates $33.64 million in revenue each year. The technology company earns $-11.24 million in net income (profit) each year or ($0.53) on an earnings per share basis.

How many employees does iCAD have?

iCAD employs 136 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The official website for iCAD is www.icadmed.com. The technology company can be reached via phone at (603) 882-5200, via email at jeremy@lifesciadvisors.com, or via fax at 603-880-3843.

This page (NASDAQ:ICAD) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.